Claim edits policy
In a partnership with MagellanRX, on September 1, 2015, Moda implemented a claim check program for injectable and/or infusion medications.
The claim check program monitors and promotes appropriate use, safety, and cost effectiveness of medications prescribed to our members. We will do this by reviewing claims for appropriate frequency, correct units, and eligible diagnosis codes.
This program will be limited to the following injectable and/or infusion medications, ordered or administered by providers. Moda applies post-service, pre-payment claims edits to diagnosis criteria and criteria for maximum units for the following medications. Prior authorization criteria do not apply for these medications. Please review the criteria below for specific covered diagnosis codes and dosing limits for each medication.
| Effective August 1, 2021 | |
|---|---|
| Brand Name | Procedure Code |
| Camcevi | J9999 |
| Effective July 1, 2020 | |
|---|---|
| Brand Name | Procedure Code |
| Azedra | C9407, C9408, A9590, A4641, A9699 |
| Hicon | A9517 |
| Lutathera | A9513 |
| Metastron | A9600 |
| Quadramet | A9604 |
| Zevalin | A9543 |
| Effective April 1, 2019 | |
|---|---|
| Brand Name | Procedure Code |
| Cinvanti | J0185 |
| Zarxio™ | Q5101 |
| Effective April 1, 2017 | |
|---|---|
| Brand Name | Procedure Code |
| Cimzia | J0717 |
| Eligard | J9217 |
| Lupron Depot | J1950 |
| Emend | J1453 |
| Fensolvi | J1951 |
| Faslodex | J9395 |
| Gemzar | J9201 |
| Trelstar Depot | J3315 |
| Vantas | J9225 |
| Xofigo | A9606 |
| Zoladex | J9202 |
- Cimzia® (certolizumab pegol)
- Cinvanti
- Leuprolide Suspension: Lupron Depot®, Lupron Depot-Ped®, Eligard®, Fensolvi®, Camcevi™
- Lutathera® (lutetium Lu 177 dotatate)
- Emend
- Faslodex® (fulvestrant)
- Gemzar® (gemcitabine)
- Metastron™ (Strontium-89 Chloride)
- Quadramet® (Samarium Sm 153 Lexidronam)
- Trelstar® (triptorelin)
- Vantas
- Xofigo
- Zarxio™ (filgrastim-sndz)
- Zevalin® (ibritumomab tiuxetan)
- Zoladex® (goserelin acetate)
As we gain better insight into utilization patterns, we will expand this initiative to cover and include more specialty and injectable drugs in the future. Updates will be posted to this page as the program is expanded.
This program will be limited to claims reviewed and to medications injected and/or infused in a professional office, home or outpatient setting.
Claims submitted after September 1, 2015 will be reviewed against clinical guidelines. If the services billed do not meet the guidelines, the claims will be subject to review and potentially disallowed.
We appreciate your partnership to improve the quality, value, and coordination of care for our members and your patients. As your partner in this evolving journey, we are committed to providing service excellence in process improvement.
Questions?
We're here to help. If you have questions, please contact our Provider Relations department at providerrelations@modahealth.com.
Questions?
If you can't find an answer, please feel free to contact our Customer Service Customer Service Customer Service
Questions?
If you can't find an answer, please feel free to contact our Customer Service
Employer web tools
Benefit Tracker
Check benefits, eligibility, incentive and utilization
Producer web tools
- Fully Insured Quotes (1-50)
- Equal Funding Quotes (25-99)
- Corporate reports
- eCommissions
Hello.
We have exciting news to share. ODS is changing its name to Moda Health.
Moda comes from the latin term "modus" and means "a way". We picked it because that's what we are here to do: help our communities find a way to better health.
Together, we can be more, be better.
Please select the state you live in, or the state where your employer is headquartered, so we can tailor your experience:
Hello.
Please select the state you live in, or the state where your employer is headquartered, so we can tailor your experience:
Changing your location to Oregon
You can return to your previous location in the site header.